Efstratios Stylianos Pyrgelis | Neurochemistry | Best Researcher Award

Published on by Neuroscientists

Dr. Efstratios Stylianos Pyrgelis | Neurochemistry | Best Researcher Award

Dr. Efstratios Stylianos Pyrgelis | National and Kapodistrian University of Athens | Greece

Dr. Efstratios-Stylianos Pyrgelis is a distinguished Neurologist and Ph.D. scholar affiliated with the National and Kapodistrian University of Athens. His extensive research contributions span neurochemistry, neuroimaging, and normal pressure hydrocephalus, reflecting a deep commitment to advancing clinical neuroscience. With over 40 published articles in SCI- and Scopus-indexed journals and authorship of 4 international medical books, Dr. Pyrgelis has established a strong academic footprint. His scholarly influence is demonstrated by a total of 510 citations, an h-index of 11, and an i10-index of 12, as recorded on Google Scholar. As a Review Editor for Frontiers in Neurology and Guest Editor for Diagnostics, he plays a pivotal role in shaping contemporary neurological research. He collaborates with the CNS Alliance Research Group and maintains professional memberships with the Greek Neurologic Society and the Medical Association of Chios. Beyond academia, he has contributed to consultancy projects linking research with clinical applications. Through his innovative work and international collaborations, Dr. Pyrgelis continues to contribute significantly to the understanding and treatment of neurological disorders, reinforcing his reputation as one of Greece’s leading researchers in the field of neuroscience.

Profiles: Orcid | Research Gate

Featured Publications

Pyrgelis, E.-S., Paraskevas, G. P., Constantinides, V. C., Boufidou, F., Stefanis, L., & Kapaki, E. (2024). In vivo prevalence of beta-amyloid pathology and Alzheimer’s disease co-pathology in idiopathic normal-pressure hydrocephalus—Association with neuropsychological features. Biomedicines, 12(8), 1898.

Pyrgelis, E.-S., Paraskevas, G. P., Constantinides, V. C., Boufidou, F., Papaioannou, M., Stefanis, L., & Kapaki, E. (2023). Alzheimer’s disease CSF biomarkers as possible indicators of tap-test response in idiopathic normal pressure hydrocephalus. Brain Sciences, 13(11), 1593.

Angelopoulou, E., Pyrgelis, E.-S., Ahire, C., Suman, P., Mishra, A., & Piperi, C. (2023). Functional implications of protein arginine methyltransferases (PRMTs) in neurodegenerative diseases. Biology, 12(9), 1257.

Pyrgelis, E.-S., Velonakis, G., Papageorgiou, S. G., Stefanis, L., Kapaki, E., & Constantinides, V. C. (2023). Imaging markers for normal pressure hydrocephalus: An overview. Biomedicines, 11(5), 1265.

Constantinides, V. C., Paraskevas, G. P., Boufidou, F., Bourbouli, M., Pyrgelis, E.-S., Stefanis, L., & Kapaki, E. (2023). CSF Aβ42 and Aβ42/Aβ40 ratio in Alzheimer’s disease and frontotemporal dementias. Diagnostics, 13(4), 783.

Constantinides, V. C., Boufidou, F., Bourbouli, M., Pyrgelis, E.-S., Ghika, A., Koros, C., Liakakis, G., Papageorgiou, S., Stefanis, L., Paraskevas, G. P., et al. (2023). Application of the AT(N) and other CSF classification systems in behavioral variant frontotemporal dementia. Diagnostics, 13(3), 332.

Angelopoulou, E., Pyrgelis, E.-S., & Piperi, C. (2022). Emerging potential of the phosphodiesterase (PDE) inhibitor ibudilast for neurodegenerative diseases: An update on preclinical and clinical evidence. Molecules, 27(23), 8448.

Fawad Ali Shah | Neuropharmacology |

Published on by Neuroscientists

Dr. Fawad Ali Shah | Neuropharmacology | Best Researcher Award

Dr. Fawad Ali Shah,  Prince Sattam bin Abdulaziz University, Saudi Arabia.

Dr. Fawad Ali Shah is an accomplished neuroscientist and pharmacologist whose academic journey began with a Pharm-D from the University of Malakand, Pakistan, and culminated in a Ph.D. in Neuroscience and Pharmacology from Gyeongsang National University, South Korea. With a strong foundation in neuroprotective pharmacology, his doctoral and postdoctoral research has focused on natural therapeutic agents for cerebral ischemia and brain injury. Professionally, he has held key academic roles in Pakistan, South Korea, Canada, and Saudi Arabia, currently serving as an Associate Professor at Prince Sattam Bin Abdulaziz University.

Profile

Scopus

🎓 Early Academic Pursuits

Dr. Fawad Ali Shah embarked on his academic journey with a profound interest in pharmaceutical sciences and neuroscience. He earned his Doctor of Pharmacy (Pharm-D) degree from the University of Malakand, Khyber Pakhtunkhwa, Pakistan, in 2010 with a First Division and a solid 70.88% score. His thesis, which explored ischemic and reperfusion injuries and their clinical implications, laid a strong foundation for his lifelong dedication to the neuropharmacological sciences. Driven by a deeper quest for knowledge, he pursued his Ph.D. at the esteemed Gyeongsang National University (GNU) in South Korea, where he specialized in neuroscience and pharmacology. Graduating with an A+ average in 2017, his doctoral research focused on investigating the neuroprotective effects of natural drug substances in models of cerebral ischemic injury. This blend of clinical insight and experimental pharmacology set the stage for his career in neuropharmacological research.

🧠 Professional Endeavors in Neuroscience

After earning his doctorate, Dr. Shah’s professional journey took a dynamic course across academia and clinical research institutions. He began as a Research Scholar and Lab Coordinator in the Neurobiology and Brain Histology Lab at GNU, deepening his technical expertise in neurohistology and preclinical pharmacology. Following this, he was appointed as Assistant Professor and then promoted to Associate Professor at Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad. His academic ascent continued with two prestigious postdoctoral positions: a lab-based postdoctoral fellowship at Robarts Research Institute, University of Western Ontario, Canada, and another at the University of Toronto. In 2022, he joined Prince Sattam Bin Abdulaziz University, Saudi Arabia, as an Associate Professor in the Department of Pharmacology and Toxicology. His teaching and mentorship roles have nurtured aspiring pharmacists and neuroscientists alike, while his hands-on work as a former Associate Pharmacist at GlaxoSmithKline (GSK) and Biogenics added vital industry experience to his academic pursuits.

🔬 Research Focus and Scientific Contributions

Dr. Shah’s research is anchored in the exploration of neuroprotective strategies, particularly involving natural drug substances in mitigating cerebral ischemia and related neuronal injuries. His scientific endeavors are characterized by a translational approach—bridging preclinical findings with potential therapeutic implications. Through a series of methodical investigations during his Ph.D. and postdoctoral tenures, he contributed to the understanding of ischemic brain injury mechanisms, drug-induced neuroprotection, and histopathological changes associated with brain trauma. He has significantly advanced the neuropharmacology discipline by contributing original research that addresses real-world health challenges, such as stroke and neurodegenerative conditions. His collaborations in Canadian research institutions have further enriched his methodological expertise and international research exposure.

📚 Teaching Excellence and Academic Impact

As a seasoned academic, Dr. Shah has been instrumental in delivering rigorous pharmacology and toxicology curricula to undergraduate and graduate pharmacy students. His dual role as a researcher and educator has empowered students with both theoretical understanding and laboratory proficiency. His mentorship extends beyond the classroom, guiding research projects and helping students build critical thinking in experimental neuroscience. His affiliation with academic institutions in Pakistan, South Korea, and Saudi Arabia demonstrates his global academic influence and his ability to adapt to diverse educational environments. His role in curriculum development and departmental leadership has contributed to the overall elevation of academic standards wherever he has served.

🏅 Recognition and Accolades

Dr. Fawad Ali Shah is an HEC (Higher Education Commission) Approved Supervisor, a recognition that attests to his academic merit and capability to guide M.Phil. and Ph.D. research. His scholarly distinction, demonstrated by first-class academic performance and international postdoctoral achievements, has earned him esteem in both academic and research circles. His involvement with reputed institutions like the University of Toronto and Robarts Research Institute has positioned him among globally recognized neuroscientists contributing to pharmacological innovation and brain research.

🌍 Global Reach and Influence

Dr. Shah’s academic and research footprints span several continents, including Asia, North America, and the Middle East. His international collaborations and transdisciplinary research have helped forge global scientific alliances. Through participation in international conferences, seminars, and research initiatives, he has disseminated key findings in neuropharmacology and inspired academic exchanges. His commitment to ethical and impactful research, along with his cross-border academic contributions, highlights his role as a globally engaged scholar advancing neuroscience for public health benefits.

🔮 Vision, Legacy, and Future Contributions

Looking ahead, Dr. Shah envisions expanding the therapeutic potential of natural compounds in managing neurodegenerative and cerebrovascular diseases. He aspires to establish advanced neuropharmacology labs in collaboration with global research centers to facilitate translational research and innovative drug discovery. His legacy lies in nurturing a new generation of neuroscientists, fostering research with clinical relevance, and strengthening the bridge between pharmaceutical education and neurological care. With a growing portfolio of impactful publications and international engagements, Dr. Shah is poised to remain a leading voice in neurotherapeutics and pharmacological innovation.

Publication

  1. Title: Carvacrol attenuated haloperidol-induced Parkinson’s disease via TNF/NFκβ-NLRP3-mediated pyroptosis
    Author(s): Not listed
    Year: 2025
    Journal: Laboratory Animal Research

 

  1. Title: In Silico molecular docking and molecular dynamic simulation of transferrin coated Phenytoin loaded SLNs with molecular targets of epilepsy
    Author(s): Not listed
    Year: 2025
    Journal: PLOS ONE

 

  1. Title: Carvacrol attenuated myocardial infarction through NLRP3-mediated pyroptosis and mTOR/Nrf2/PPARγ-dependent autophagic signaling
    Author(s): Not listed
    Year: 2025
    Journal: Toxicology and Applied Pharmacology

 

  1. Title: Retraction notice to “Quercetin attenuated ischemic stroke induced neurodegeneration by modulating glutamatergic and synaptic signaling pathways”
    Author(s): Not listed
    Year: 2024
    Journal: Heliyon

 

  1. Title: Ghrelin’s modulation of growth hormone secretagogue receptors in primary glioblastoma and meningioma: A comprehensive in-vitro study
    Author(s): Not listed
    Year: 2025
    Journal: Biochemical and Biophysical Research Communications

 

  1. Title: Corrigendum to “pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease”
    Author(s): Not listed
    Year: 2024
    Journal: European Journal of Pharmaceutics and Biopharmaceutics

 

  1. Title: Punicalagin improves inflammation and oxidative stress in rat model of pelvic inflammatory disease
    Author(s): Not listed
    Year: 2025
    Journal: Natural Product Research

 

  1. Title: Core-shell tablets designed for modified and sequential release of ibuprofen and rabeprazole
    Author(s): Not listed
    Year: 2024
    Journal: International Journal of Pharmaceutics

 

  1. Title: Effect of Bacillus clausii in attenuating symptoms of DSS-induced ulcerative colitis by modulating NFkB pathway and oxidative stress in mice
    Author(s): Not listed
    Year: 2024
    Journal: Clinical and Experimental Pharmacology and Physiology

 

  1. Title: Paroxetine Loaded Nanostructured Lipid Carriers Based In-situ Gel for Brain Delivery via Nasal Route for Enhanced Anti-Depressant Effect: In Vitro Prospect and In Vivo Efficacy
    Author(s): Not listed
    Year: 2024
    Journal: AAPS PharmSciTech

 

🧾 Conclusion

Dr. Fawad Ali Shah stands out as a dedicated researcher, educator, and global academic contributor in the fields of neuroscience and pharmacology. His blend of international experience, pioneering research on natural neuroprotective agents, and commitment to academic excellence underscores his significant role in the advancement of neurotherapeutics. As he continues to inspire future scientists and lead innovative research, his impact will resonate across both the scientific and clinical communities, shaping the future of neurological health and pharmaceutical sciences.